Long-term Anticoagulation in a Patient With Severe Hemophilia A

NCT07314983 | Recruiting

• 1 other identifier: 9816
• Study Type: observational
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Conditions

Hemophilia A

Keywords

Hemophilia A; Severe Hemophilia A; factor VIII (FVIII) deficiency; Antithrombotic protection; Anticoagulant therapy

Outcome Measures

Primary Outcomes (1)

• FVIII Level

  Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding. Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery. General values: * Normal: approximately 50 to 150% * Too low: risk of bleeding * Too high: may increase the risk of clots

  Up to 15 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient (≥ 18 years) with severe hemophilia A

You may qualify if:

• Adult patient (≥ 18 years) with severe hemophilia A
• Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.

You may not qualify if:

• \- Subject having expressed objection to the reuse of their data for scientific research

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Hemophilia A

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Laurent SATTLER, PharmD

CONTACT

33 3 88 12 75 28; laurent.sattler@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: January 2, 2026
• Study Start: September 22, 2025
• Primary Completion: January 1, 2026
• Study Completion: January 31, 2026
• Last Updated: January 2, 2026

Record last verified: 2025-09

Locations

FR (1)